The Trader

Tapestry has risen well over 25% this year. That has left some wondering how much farther it can rally. One analyst’s answer: nearly 20%.

Evercore ISI screened for small-caps that are in the highest quintile of profitability based on net profit margins and return on equity.

The index still has to trade a new high, something that would be easier to do if it can surpass 6079, a key technical level.

One year after being beaten down by controversy, the brokerage is a growth stock again.

The index is having trouble staying above the 6000 level, indicating that not enough has changed in the economic environment to stoke confidence that stocks could soar from here.

After an early 2025 run, shares have fallen about 9% from their April high. But there’s nothing wrong with Kroger.

Staples, utilities, and healthcare have fallen out of favor since President Donald Trump’s tariff reversal. They could be ready to rally.

Wall Street seems to have breathed a sigh of relief and now expects the tariffs will be less draconian. But much remains in play.

The retailer has strung together a remarkable record of sales growth that makes the stock look like a bargain.

Palantir stock has hammered short sellers this year.

Corporate profits may be the only thing standing between a bleak future and something brighter. Nvidia, we’re counting on you.

Smaller companies could benefit if the Trump administration focuses more on domestic economic stimulus and less on tariffs and trade.

IBM is priced at a premium to the market without Mag Seven-like levels of profit growth

Shares of Puma, Deckers Outdoors, Nike, and other shoemakers soared after the U.S. and China agreed to pause levies over the weekend.

A trade war was averted, and artificial intelligence made a grand return. What else could you ask for?

The company’s shares have gotten too cheap to ignore.

Investors want trade deals, but the state of negotiations remains fragile. Much of the good news already appears to be reflected in the stock market.

When Microsoft released better-than-expected earnings on May 1, it wasn’t just a gift to its shareholders, but for all software companies. Salesforce stands to gain.

A slowdown isn’t guaranteed. Look at banks, retail, and copper if one doesn’t materialize.

Investors are muddling through earnings season without a clear picture of where companies are headed. They will have to outline their exposure more specifically in the months ahead, and that could cause a more dramatic market reaction.

Higher profitability hasn’t been reflected in refiner stocks. That opens up some opportunities.

Steady stock repurchases are an indicator of management confidence. Pinterest, Devon, AES, Trex, and Enphase are all scooping up shares.

Sure, there are reasons for optimism. But there may be too many risks to justify jumping into U.S. stocks at these levels. The outperformance of many international markets could continue.

There are plenty of compelling opportunities in the sector due to innovative medications and treatments being developed through genomics research.

The stock is up nearly 18% this year and trading near a record high despite the turmoil on Wall Street.